Clinical Trials | May 20, 2022
Motilal Oswal Private Equity (MOPE) invests in Pathkind Diagnostics
A primary investment of Rs 194.4 crore has been made
A primary investment of Rs 194.4 crore has been made
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
